| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Dept of Respiratory Diseases, Ghent University Hospital, Ghent, Belgium
CORRESPONDENCE: N.J. Vanacker, Dept of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, B-9000, Ghent, Belgium. Fax: 32 92402341. E-mail: Nele.Vanacker@barclab.com
Keywords: asthma, corticosteroids, dose-response, fluticasone, rats, remodelling
Received: December 12, 2001
Accepted May 28, 2002
N.J. Vanacker is funded by the FWO-Flanders (Fund for Scientific Research, Flanders). This work was supported in part by the Concerted Research Initiative of the University of Ghent (Project no. GOA 98-6) and by the FWO-Flanders (Project no. 3G006298).
To examine whether fluticasone propionate (FP) dose-dependently inhibits inflammatory as well as structural changes, Brown Norway rats were sensitised to ovalbumin (OA) on day 0 and 7. From day 14–28, rats were exposed to aerosolised OA (1%) or phosphate buffered saline every 2 days. Thirty minutes before each allergen exposure, animals were pre-treated with aerosolised placebo or FP (0.1, 1 or 10 mg) or prednisolone 3 mg·kg–1 i.p.
At day 29, 0.1 mg FP had no measurable effect, either on inflammatory or structural changes, such as goblet cell hyperplasia and airway wall thickening. The allergen-induced increase in eosinophilic inflammation in bronchoalveolar lavage fluid and in the airway mucosa, as well as increased fibronectin deposition, were inhibited by treatment with FP from a dose of 1 mg onwards. Inhibition of goblet cell hyperplasia and thickening of the airway wall required 10 mg inhaled FP. At this dose, systemic effects were observed. However, for a comparable degree of systemic activity, prednisolone was far less effective at preventing airway changes.
The dose of inhaled fluticasone propionate required to inhibit allergen-induced structural alterations was higher than to prevent eosinophil influx, and caused systemic side-effects. However, for a similar systemic activity, prednisolone was ineffective in preventing airway remodelling.
This article has been cited by other articles:
|
|
 |
|
  A. M. Misior, H. Yan, R. M. Pascual, D. A. Deshpande, R. A. Panettieri, and R. B. Penn Mitogenic Effects of Cytokines on Smooth Muscle Are Critically Dependent on Protein Kinase A and Are Unmasked by Steroids and Cyclooxygenase Inhibitors Mol. Pharmacol., February 1, 2008; 73(2): 566 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Eur. Respir. J., September 1, 2007; 30(3): 574 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salter, K. Biggadike, J. L. Matthews, M. R. West, M. V. Haase, S. N. Farrow, I. J. Uings, and D. W. Gray Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L660 - L667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tomic, C. C. Lassiter, J. D. Ritzenthaler, H. N. Rivera, and J. Roman Anti-Tissue Remodeling Effects of Corticosteroids: Fluticasone Propionate Inhibits Fibronectin Expression in Fibroblasts Chest, January 1, 2005; 127(1): 257 - 265. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
